KORU Medical Systems’ (KRMD) Neutral Rating Reaffirmed at Piper Sandler

Piper Sandler reiterated their neutral rating on shares of KORU Medical Systems (NASDAQ:KRMD) in a report published on Wednesday morning,Benzinga reports. Piper Sandler currently has a $4.50 price target on the stock, down from their previous price target of $5.00.

KRMD has been the subject of a number of other research reports. Weiss Ratings lowered shares of KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 29th. Craig Hallum reaffirmed a “buy” rating and issued a $6.00 price target on shares of KORU Medical Systems in a research report on Thursday, August 6th. Zacks Research downgraded KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 30th. Finally, Wall Street Zen lowered KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.50.

KORU Medical Systems Price Performance

NASDAQ:KRMD opened at $3.89 on Wednesday. The company’s 50 day moving average is $3.13 and its 200-day moving average is $3.94. KORU Medical Systems has a 12 month low of $2.86 and a 12 month high of $6.61.

KORU Medical Systems (NASDAQ:KRMD) last posted its quarterly earnings data on Tuesday, November 10th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.04. KORU Medical Systems had a negative net margin of 1.78% and a negative return on equity of 4.75%. The business had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.33 million. Sell-side analysts forecast that KORU Medical Systems will post -0.02 EPS for the current year.

Insider Activity at KORU Medical Systems

In other KORU Medical Systems news, insider Adam Kalbermatten acquired 32,000 shares of KORU Medical Systems stock in a transaction dated Tuesday, September 8th. The stock was bought at an average cost of $3.16 per share, with a total value of $101,120.00. Following the completion of the transaction, the insider owned 394,017 shares of the company’s stock, valued at $1,245,093.72. The trade was a 8.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 18.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On KORU Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of KRMD. White Pine Capital LLC acquired a new position in KORU Medical Systems during the 3rd quarter valued at $840,000. Squarepoint Ops LLC grew its position in KORU Medical Systems by 858.0% in the 2nd quarter. Squarepoint Ops LLC now owns 124,755 shares of the company’s stock worth $524,000 after purchasing an additional 111,733 shares during the last quarter. Bank of America Corp DE bought a new position in shares of KORU Medical Systems during the 2nd quarter worth about $124,000. Meros Investment Management LP bought a new position in shares of KORU Medical Systems during the 2nd quarter worth about $3,190,589. Finally, Algert Global LLC increased its holdings in shares of KORU Medical Systems by 57.2% during the 2nd quarter. Algert Global LLC now owns 22,737 shares of the company’s stock worth $95,000 after purchasing an additional 8,270 shares during the period. Institutional investors and hedge funds own 58.60% of the company’s stock.

Key Stories Impacting KORU Medical Systems

These are some of the KRMD stories that stood out recently:

• Positive Sentiment: Third-quarter adjusted earnings were $0.02 per share, versus analyst expectations for a $0.02 loss. Revenue of $11.57 million also exceeded the $11.33 million consensus estimate. KORU Medical Q3 2026 earnings
• Positive Sentiment: KORU lifted its 2026 revenue outlook to $48.0 million–$48.5 million; the midpoint is slightly above the $48.0 million analyst consensus. The company also expects year-end cash to exceed $8 million. Revenue outlook and cash target
• Neutral Sentiment: Piper Sandler maintained its “neutral” rating but cut its price target to $4.50 from $5.00. The revised target still implies potential upside from the referenced $3.89 share price.

About KORU Medical Systems

KORU Medical Systems, Inc. develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems. KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.